As said, I am no advocate of RCE. I get why you and others are quite rightly very unhappy with RCE management. Its indeed why I never bought before. My discussion was specifically on these results (I actually agreed with Zecs that the data released was poor - it should have included at least the Lipsky scale scores IMO) and some of the questionable comments on.
I get it. This management leave a lot to be desired and I am a recent blow-in. That's a separate discussion. Beware family unprofitable business ventures listed as public companies. The Board looks a bit better now with Penderghast as Chair. Both he and Dunton weren't exactly expansive on data in interview on this report either, but could have been editing. The data should have irrefutably been better in the ASX release that they can control.
C-. Need to improve, Dunton particularly in communicating trial results to investors/capital mkts they continue to rely on to be a going concern. But the primary endpoint was met in this Phase II trial of "Recce's goop".
RCE Price at posting:
43.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)